Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 11/20 | 0.67 |
| ▸ | RAB9A | P51151 | 11/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.63 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.63 |
| ▸ | RELA | Q04206 | 3/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | BUB1 | O43683 | 1/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.59 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27259578 | 0.88 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL6951826 | 0.86 | BUB1 (0.56) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL27634788 | 0.84 | NPC1 (0.84) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL32674581 | 0.84 | NPC1 (0.84) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL30945514 | 0.82 | BUB1 (0.53) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL9358641 | 0.82 | RAB9A (0.66) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL11725599 | 0.81 | RAB9A (0.60) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL21568165 | 0.81 | KMT2A (0.67) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL11421487 | 0.81 | RAB9A (0.77) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL1842324 | 0.81 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040116418-A1 | Compounds and methods for inhibition of HIV and related viruses | MEDIVIR AB (SE) | 2004-06-17 | — | — | US | disclosed |
| US-20020132794-A1 | Compounds and methods for inhibition of HIV and related viruses | MEDIVIR AB | 2002-09-19 | — | — | US | disclosed |
| US-6376492-B1 | GUANIDINE DERIVATIVES | MEDIVIR AB (SE) | 2002-04-23 | — | — | US | disclosed |
| US-5849769-A | N-arylalkyl-N-heteroarylurea and guandine compounds and methods of treating HIV infection | MEDIVIR AB (SE) | 1998-12-15 | — | — | US | disclosed |
| EP-0706514-B1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1998-11-18 | — | — | EP | disclosed |
| EP-0706514-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1996-04-17 | — | — | EP | disclosed |
| WO-1995006034-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1995-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132794-A1 | Compounds and methods for inhibition of HIV and related viruses | POLRMT, POLM, POLR1E | NPC1 1253/4885RAB9A 3313/4885SMN1; SMN2 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.